NCT06840704

Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer

Immunonutrition in Reducing Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer: a Prospective, Randomized, Controlled, Open-label Clinical Trial

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 121 (estimated)
• Sponsor: Hunan Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy of immunonutrition in reducing acute esophagitis after thoracic radiotherapy in lung cancer.

Detailed description

This is a prospective, randomized, controlled, open-label clinical trial, which aimed to explore the efficacy and safety of oral immunonutrition therapy in reducing acute esophagitis after thoracic radiotherapy in lung cancer patients.

Conditions

• Non Small Cell Lung Cancer
• Small Cell Lung Cancer

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Oral immunonutrition	Oral immunonutrition (Oral Impact®, Nestlé), 250 ml per bottle, with a dosage of 2 bottles per day, starting on the day of radiotherapy and continuing for three weeks after radiotherapy.

Timeline

• Start date: 2025-02-25
• Primary completion: 2026-06-30
• Completion: 2026-12-30
• First posted: 2025-02-21
• Last updated: 2026-04-02

Locations

6 sites across 1 country: China